BDSXNasdaqServices-Medical LaboratoriesFiscal year ends December 31
BIODESIX INC
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$23.40−0.26 (-1.10%)
Close on Oct 19, 2026
- Market cap
- $240.93M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2018 to 2025
Operating margin
-31.5%+18.8 pts over 5 years
Net margin
-39.8%+103.8 pts over 5 years
Growth rates
Compound annual growth to fiscal 2025
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +24.1% | +32.3% | +14.2% | – |
Returns and balance sheet
8 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2018 | FY2020 | FY2025 | Trend |
|---|---|---|---|---|
| Return on equity | – | 71.1% | -383.1% | |
| Return on assets | – | -78.8% | -38.2% | |
| Current ratio | – | 2.68 | 1.86 | |
| Debt to equity | – | 0.39 | -19.25 | |
| Net debt to EBITDA | – | 2.32× | -1.28× | |
| Interest coverage | – | -3.0× | -3.6× | |
| Capex to revenue | – | 4.3% | 0.3% | |
| Diluted shares | – | 5M | 8M |
Where the cash went
Fiscal 2021 to 2025, five years combined
Biodesix generated $167.99M from operations and spent $31.95M on capital expenditure, dividends and share buybacks. 100% of that went back into the business.
Generated
$167.99M
Used
$31.95M
Capital expenditure$31.95M100%Dividends$00%Share buybacks$00%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-39.8%
×Asset turnover0.96×
×Equity multiplier10.03×
=Return on equity, FY2025-383.1%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2025 | -39.8% | 0.96× | 10.03× | -383.1% |
| FY2024 | -60.2% | 0.73× | 7.71× | -337.3% |
| FY2023 | -106.2% | 0.51× | 7.62× | -414.1% |
| FY2022 | -171.3% | 0.45× | 4.19× | -324.5% |
| FY2021 | -79.2% | 0.55× | 3.24× | -141.8% |
| FY2020 | -143.7% | 0.55× | -0.90× | 71.1% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2025 against fiscal 2024
3of 8 tests passed in fiscal 2025. Some tests lack the figures they need.
- ProfitableNet income above zero-$35.27M
- Cash generatingOperating cash flow above zero-$23.27M
- Return on assets improvedROA up on the prior year-43.3% → -36.3%
- Earnings backed by cashOperating cash flow above net income-$23.27M vs -$35.27M
- Less leverageLong-term debt to assets fell37.4% → 54.2%
- Better liquidityCurrent ratio rose2.76 → 1.86
- No dilutionShare count did not rise6M → 8M
- Gross margin improvedGross margin up on the prior year– → –
- More efficientAsset turnover rose0.72 → 0.91